Aditxt, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ADTX Nasdaq 2836 www.aditxt.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aditxt, Inc.

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025 - Oct 29th, 2025 2:30 pm
BC-Most Active Stocks - Oct 28th, 2025 8:30 am
Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market - Oct 27th, 2025 6:30 am
Evofem Announces Voting Results from Special Meeting of Stockholders - Oct 20th, 2025 2:18 pm
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms - Sep 11th, 2025 7:18 am
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting - Sep 9th, 2025 7:28 am
Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030 - Aug 25th, 2025 7:15 am
Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law - Aug 21st, 2025 6:56 am
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update - Aug 14th, 2025 6:46 am
Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference - Aug 5th, 2025 6:46 am
Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases - Jul 29th, 2025 7:00 am
Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test - Jul 24th, 2025 6:15 am
Aditxt to Present at Wall Street Reporter’s Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET - Jul 22nd, 2025 6:15 am
Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy - Jul 15th, 2025 7:12 am
Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET - Jun 26th, 2025 6:15 am
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors - Jun 9th, 2025 6:15 am
Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6 - Jun 5th, 2025 6:15 am
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. - May 19th, 2025 6:00 am
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics - May 19th, 2025 6:00 am
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ - May 2nd, 2025 7:00 am